Advertisement
Screener

EXAGEN INC. (XGN) Debt / Equity

EXAGEN INC. (XGN) Debt / Equity

  • 2026-06-30: Debt/Equity Ratio 1.87.
  • 2026-03-31: Debt/Equity Ratio 1.58.
  • 2025-12-31: Debt/Equity Ratio 1.31.
  • 2025-09-30: Debt/Equity Ratio 1.26.

Complete source-backed debt/equity ratio history.

Available history
2021-12-31 to 2026-06-30
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity Ratio
2026-06-301.87
2026-03-311.58
2025-12-311.31
2025-09-301.26
2025-06-301.09
2025-03-313.27
2024-12-312.12
2024-09-301.57
2024-06-301.15
2024-03-310.98
2023-12-310.86
2023-09-300.71
2023-06-300.61
2023-03-310.82
2022-12-310.68
2021-12-310.32

Annual Debt/Equity Ratio

DateDebt/Equity Ratio
2025-12-311.31
2024-12-312.12
2023-12-310.86
2022-12-310.68
2021-12-310.32

Similar stocks

Stock NameCountryMarket CapPE Ratio
Freenome, Inc. (FRNM)United States$0.143B
BIODESIX INC (BDSX)United States$0.312B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45